[P02BB01, trichlorfon, The therapeutic efficacy of Atropine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Atropine is combined with Antipyrine.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01EC01, sulfamethoxazole, Atropine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Atropine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Atropine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Atropine is combined with Sulindac.]
[N05AL01, sulpiride, Atropine may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Atropine is combined with Azapropazone.]
[N06DA01, tacrine, The therapeutic efficacy of Atropine can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Atropine is combined with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Atropine is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Atropine.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01AC01, thiotepa, The therapeutic efficacy of Atropine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Atropine is combined with Thiopental.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Thioridazine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BB04, aprindine, Atropine may increase the arrhythmogenic activities of Aprindine.]
[B02AB01, aprotinin, The therapeutic efficacy of Atropine can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Atropine is combined with Moxisylyte.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Atropine is combined with Tilidine.]
[S01ED01, timolol, Timolol may increase the arrhythmogenic activities of Atropine.]
[P01AB02, tinidazole, Atropine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[M02AX02, tolazoline, Atropine may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Atropine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Atropine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Atropine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Atropine.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03AA06, trichlormethiazide, Atropine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Atropine is combined with Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Atropine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atropine.]
[A03AA05, trimebutine, Atropine may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Atropine may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Atropine.]
[C02BA01, trimethaphan, Atropine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Atropine is combined with Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Atropine is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA09, azilsartan medoxomil, Atropine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Atropine can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Vandetanib.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Atropine.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Atropine is combined with Indacaterol.]
[C08DA01, verapamil, Atropine may increase the arrhythmogenic activities of Verapamil.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01CA01, vinblastine, Vinblastine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C04AX07, vincamine, Atropine may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Atropine is combined with Xenon.]
[C03BA10, xipamide, Atropine may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Atropine is combined with Zuclopenthixol.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Atropine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Atropine is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Atropine is combined with Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Atropine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Atropine.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Atropine which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Atropine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Atropine is combined with Mirabegron.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Atropine.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Atropine is combined with Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Atropine is combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Atropine.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Rasagiline is combined with Atropine.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Atropine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06DA02, donepezil, The therapeutic efficacy of Atropine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Atropine is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Atropine.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Atropine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Atropine is combined with Bedaquiline.]
[C04AX11, bencyclane, Atropine may increase the arrhythmogenic activities of Bencyclane.]
[C03AA01, bendroflumethiazide, Atropine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Atropine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Gemifloxacin.]
[M04AB03, benzbromarone, Atropine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Atropine.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Atropine.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Atropine.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Atropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Atropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Atropine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08EA02, bepridil, Atropine may increase the arrhythmogenic activities of Bepridil.]
[C02KX05, riociguat, Atropine may decrease the antihypertensive activities of Riociguat.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C02KX04, macitentan, Atropine may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Atropine is combined with Droxidopa.]
[C07AB04, acebutolol, Atropine may increase the arrhythmogenic activities of Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A16AA06, betaine, The therapeutic efficacy of Atropine can be decreased when used in combination with Betaine.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Atropine.]
[C02CC01, bethanidine, Atropine may decrease the antihypertensive activities of Bethanidine.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ceritinib.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Atropine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Atropine is combined with Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Atropine is combined with Eliglustat.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[V04CX03, methacholine, Atropine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Atropine.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Atropine is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Atropine is combined with Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Atropine.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Atropine is combined with Panobinostat.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Atropine is combined with Difemerine.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Atropine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Atropine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Atropine.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Atropine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Atropine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[B01AC27, selexipag, Atropine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Atropine.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Atropine is combined with Alminoprofen.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Atropine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C07AA19, bupranolol, Atropine may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Atropine is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Atropine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Atropine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Atropine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Atropine is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Atropine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Atropine.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Atropine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Atropine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Atropine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Atropine is combined with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09AA07, benazepril, Atropine may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Atropine.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Safinamide is combined with Atropine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Atropine.]
[P03AC02, bioallethrin, Atropine may increase the arrhythmogenic activities of Bioallethrin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Atropine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Atropine can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Atropine is combined with Bitolterol.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Atropine is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03BA02, budesonide, Atropine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Atropine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Atropine is combined with Bumadizone.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01AA02, acetyldigoxins, Atropine may increase the arrhythmogenic activities of Acetyldigoxin.]
[N01BX04, capsaicin, The therapeutic efficacy of Atropine can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Atropine.]
[C09AA01, captopril, Atropine may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Atropine.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Atropine.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Atropine is combined with Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C07AG02, carvedilol, Atropine may increase the arrhythmogenic activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Atropine is combined with Cannabidiol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Encorafenib.]
[C07AB08, celiprolol, Atropine may increase the arrhythmogenic activities of Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ivosidenib.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Atropine is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Atropine is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Atropine.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Atropine is combined with Revefenacin.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Atropine.]
[C01BG07, cifenline, Atropine may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, Atropine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Atropine.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01ED05, carteolol, Atropine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Atropine.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Atropine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Atropine is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Atropine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Atropine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA06, candesartan, Atropine may decrease the antihypertensive activities of Candesartan.]
[J01DC04, cefaclor, Atropine may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03BX03, cicletanine, Atropine may increase the arrhythmogenic activities of Cicletanine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Entrectinib.]
[N07XX11, pitolisant, Atropine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Atropine.]
[C03AA09, cyclothiazide, Atropine may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Atropine.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Atropine is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Atropine.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Atropine is combined with Dutasteride.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Atropine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Atropine.]
[C08CA16, clevidipine, Atropine may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Atropine may increase the arrhythmogenic activities of Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Atropine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02AA06, methoserpidine, Atropine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Atropine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Atropine is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Atropine.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Atropine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Atropine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Atropine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08CA17, levamlodipine, Atropine may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Atropine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Atropine.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01FX15, belantamab mafodotin, Atropine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Atropine is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Chloroquine.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C03AA04, chlorothiazide, Atropine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03BA04, chlorthalidone, Atropine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Atropine is combined with Ethenzamide.]
[N06BX18, vinpocetine, Atropine may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Atropine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Atropine is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Atropine is combined with Berotralstat.]
[M09AA01, hydroquinine, Atropine may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Atropine.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Atropine is combined with Naxitamab.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Atropine is combined with Fenbufen.]
[C01CA19, fenoldopam, Atropine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Atropine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Atropine is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Atropine.]
[S01JA01, fluorescein, Atropine may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Atropine is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Atropine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H04AA02, dasiglucagon, Atropine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Atropine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Atropine.]
[L01XA01, cisplatin, The therapeutic efficacy of Atropine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Atropine is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Atropine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Atropine is combined with Mefenamic acid.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Atropine which could result in a higher serum level.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Atropine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Atropine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Atropine.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A05BA08, glycyrrhizic acid, Atropine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Cocaine.]
[C02KB01, metyrosine, Atropine may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Atropine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Atropine is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Atropine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Atropine is combined with Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Atropine is combined with Homatropine.]
[C01BA13, hydroquinidine, Atropine may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A04AA03, tropisetron, Atropine may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Atropine is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Atropine is combined with Indobufen.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Atropine is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Atropine can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Atropine is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Atropine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Atropine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Atropine is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Atropine.]
[C08CA09, lacidipine, Atropine may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Atropine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Atropine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Atropine is combined with Lonazolac.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Atropine is combined with Loxoprofen.]
[C09AA03, lisinopril, Atropine may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Atropine.]
[C08CA11, manidipine, Atropine may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Atropine is combined with Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Atropine is combined with Mefenorex.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Atropine.]
[C01EB10, adenosine, Atropine may increase the arrhythmogenic activities of Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Atropine.]
[C04AX01, cyclandelate, Atropine may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Atropine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03DA04, eplerenone, Atropine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, Atropine may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Atropine may decrease the antihypertensive activities of Cyclopenthiazide.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Atropine is combined with Cyclopentolate.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Atropine.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Moclobemide is combined with Atropine.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09AA13, moexipril, Atropine may decrease the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, Atropine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Atropine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Atropine is combined with Morniflumate.]
[C02AC05, moxonidine, Atropine may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Atropine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Atropine is combined with Etoricoxib.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01DB02, daunorubicin, Atropine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02CC04, debrisoquin, Atropine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Atropine is combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Atropine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C07AB12, nebivolol, Atropine may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01DX16, nicorandil, Atropine may increase the arrhythmogenic activities of Nicorandil.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Atropine is combined with Theodrenaline.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Atropine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Atropine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Atropine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Atropine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Atropine is combined with Olsalazine.]
[N06AA01, desipramine, Desipramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01AA07, deslanoside, Atropine may increase the arrhythmogenic activities of Deslanoside.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Atropine.]
[C09XA02, aliskiren, Atropine may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Atropine.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Atropine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S03BA01, dexamethasone, Dexamethasone may increase the excretion rate of Atropine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Atropine is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Atropine is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Atropine.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Atropine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Atropine is combined with Dextromoramide.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Atropine is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[V03AH01, diazoxide, Atropine may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01BC03, diclofenac, Atropine may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Atropine.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.]
[C02DG01, pinacidil, Atropine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, Atropine may increase the arrhythmogenic activities of Pinaverium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Atropine is combined with Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Atropine is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Atropine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Atropine.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Atropine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Atropine is combined with Diflunisal.]
[C01AA04, digitoxin, Atropine may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Atropine.]
[C02DB01, dihydralazine, Atropine may decrease the antihypertensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Atropine may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Atropine may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone.]
[J05AE08, atazanavir, Atropine may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC21, treprostinil, Atropine may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Atropine.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Atropine is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Atropine is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Atropine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Atropine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09AA06, quinapril, Atropine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, Atropine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Atropine is combined with Cisapride.]
[C09AA05, ramipril, Atropine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Atropine is combined with Reproterol.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Atropine.]
[N07AA03, distigmine, The therapeutic efficacy of Atropine can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, Atropine may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Atropine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Atropine.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atropine.]
[G04BE08, tadalafil, Atropine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Atropine.]
[C02KX02, ambrisentan, Atropine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Atropine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Atropine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Atropine is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Atropine is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Atropine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Atropine is combined with Dopamine.]
[N06AA16, dothiepin, Dosulepin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Atropine.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Atropine.]
[L01DB01, doxorubicin, Atropine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C10AA01, simvastatin, Atropine may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Atropine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Atropine.]
[C09AA11, spirapril, Atropine may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C07AB13, talinolol, Atropine may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Atropine.]
[G04CA03, terazosin, Atropine may decrease the antihypertensive activities of Terazosin.]
[G04BD05, terodiline, Atropine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Atropine may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Atropine is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09AA02, enalapril, Atropine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Atropine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Toloxatone is combined with Atropine.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Atropine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Atropine is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Atropine is combined with Toremifene.]
[C03CA04, torsemide, Atropine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Atropine is combined with Tramazoline.]
[C09AA10, trandolapril, Atropine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Atropine.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Atropine.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Atropine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Atropine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Atropine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Atropine is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Atropine is combined with Xamoterol.]
[S01GA03, xylometazoline, Atropine may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Atropine may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Atropine is combined with Epinephrine.]
[C09AA15, zofenopril, Atropine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Atropine is combined with Zomepirac.]
[N03AX15, zonisamide, Atropine may increase the arrhythmogenic activities of Zonisamide.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BG01, moricizine, Atropine may increase the arrhythmogenic activities of Moricizine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Atropine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Atropine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Atropine.]
[N03AD01, ethosuximide, Atropine may increase the arrhythmogenic activities of Ethosuximide.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Atropine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Atropine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Atropine is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BA05, ajmaline, Atropine may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Atropine.]
[A02BA04, nizatidine, The therapeutic efficacy of Atropine can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Atropine.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Atropine is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BB03, tocainide, Atropine may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Atropine may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Atropine.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Atropine which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Atropine.]
[C08CA02, felodipine, Atropine may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Atropine may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Atropine is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Atropine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Atropine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Atropine is combined with Salbutamol.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Atropine is combined with Flavoxate.]
[C01BC04, flecainide, Atropine may increase the arrhythmogenic activities of Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Atropine is combined with Floctafenine.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Atropine.]
[N07CA03, flunarizine, Atropine may increase the arrhythmogenic activities of Flunarizine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Atropine.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Atropine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Atropine is combined with Flupentixol.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Atropine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, Atropine may increase the arrhythmogenic activities of Fluspirilene.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Atropine is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Atropine.]
[C03CA01, furosemide, Atropine may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Atropine is combined with Amisulpride.]
[N06DA04, galantamine, The therapeutic efficacy of Atropine can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08DA02, gallopamil, Atropine may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Atropine is combined with Barbexaclone.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Atropine.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Atropine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AD03, methsuximide, Atropine may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Atropine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Atropine.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Atropine which could result in a higher serum level.]
[A10BB07, glipizide, Atropine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[H04AA01, glucagon, Atropine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Atropine.]
[C05AE01, nitroglycerin, Atropine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Atropine.]
[C02CA04, doxazosin, Atropine may decrease the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Atropine.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Atropine.]
[C09AA09, fosinopril, Atropine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Atropine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Atropine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Atropine is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Atropine.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA01, losartan, Atropine may increase the arrhythmogenic activities of Losartan.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Atropine.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Atropine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Atropine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Atropine is combined with Hexobarbital.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Atropine is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Atropine may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Atropine may increase the arrhythmogenic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Atropine is combined with Oxatomide.]
[C09AA04, perindopril, Atropine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Atropine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Atropine may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Atropine is combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, Atropine may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Atropine is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Atropine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Atropine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Atropine is combined with Ibuprofen.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Atropine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01CD01, paclitaxel, Paclitaxel may decrease the excretion rate of Atropine which could result in a higher serum level.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Terlipressin.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03BA11, indapamide, Atropine may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[C02CA02, indoramin, Atropine may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Atropine is combined with Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Atropine.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Atropine is combined with Anagrelide.]
[C07AA01, alprenolol, Atropine may increase the arrhythmogenic activities of Alprenolol.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Atropine.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Iproniazid is combined with Atropine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Isocarboxazid is combined with Atropine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Atropine.]
[C09AA16, imidapril, Atropine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Atropine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Atropine is combined with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Atropine is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Atropine is combined with Ketoprofen.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Atropine is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Atropine is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Atropine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Atropine may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Atropine is combined with Amantadine.]
[C02AA05, deserpidine, Atropine may decrease the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Atropine.]
[N07AA30, ambenonium, The therapeutic efficacy of Atropine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Atropine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Atropine.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Atropine.]
[C08EX01, lidoflazine, Atropine may increase the arrhythmogenic activities of Lidoflazine.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A07DA03, loperamide, Atropine may increase the arrhythmogenic activities of Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C10AA02, lovastatin, Lovastatin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Atropine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Atropine.]
[V04CC02, magnesium sulfate, Atropine may increase the arrhythmogenic activities of Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Nilotinib.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02BB01, mecamylamine, Atropine may decrease the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Atropine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Atropine is combined with Meclofenamic acid.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01AA08, medigoxin, Atropine may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Atropine.]
[P01BC02, mefloquine, The therapeutic efficacy of Atropine can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06DX01, memantine, The therapeutic efficacy of Atropine can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Atropine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Atropine is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Atropine is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Atropine is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Atropine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Atropine is combined with Metaraminol.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Atropine is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Atropine is combined with Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Atropine is combined with Methohexital.]
[N02BG08, ziconotide, Atropine may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Atropine is combined with Methoxamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Atropine.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Atropine.]
[C02AB01, methyldopa, Atropine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The risk or severity of hypertension can be increased when Methylene blue is combined with Atropine.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Atropine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Atropine.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Atropine.]
[C03BA08, metolazone, Atropine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Atropine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Atropine.]
[C01BB02, mexiletine, The absorption of Mexiletine can be decreased when combined with Atropine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Atropine.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Atropine is combined with Aminophenazone.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Atropine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Atropine is combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Atropine.]
[C09CA03, valsartan, Atropine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Atropine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Atropine is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Atropine.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Atropine is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Atropine is combined with Pazopanib.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Atropine is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Atropine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Atropine is combined with Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C07AA12, nadolol, Atropine may increase the arrhythmogenic activities of Nadolol.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Atropine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Atropine is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Atropine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Atropine.]
[M02AA12, naproxen, Atropine may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Atropine is combined with Remifentanil.]
[A10BX02, repaglinide, Atropine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, Atropine may increase the arrhythmogenic activities of Levosimendan.]
[S01EB06, neostigmine, The therapeutic efficacy of Atropine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Atropine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA07, telmisartan, Atropine may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Nialamide is combined with Atropine.]
[C08CA04, nicardipine, Atropine may increase the arrhythmogenic activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Atropine is combined with Nicergoline.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Atropine.]
[C08CA05, nifedipine, Atropine may increase the arrhythmogenic activities of Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Atropine is combined with Niflumic acid.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Atropine.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Atropine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08CA08, nitrendipine, Atropine may increase the arrhythmogenic activities of Nitrendipine.]
[J01XE01, nitrofurantoin, Atropine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02DD01, nitroprusside, Atropine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Atropine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Atropine.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G02CA02, nylidrin, Atropine may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atropine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ofloxacin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Atropine is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Atropine.]
[C07AA02, oxprenolol, Atropine may increase the arrhythmogenic activities of Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Atropine is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Atropine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Atropine is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Atropine is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Atropine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Atropine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Asenapine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Atropine is combined with Tapentadol.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02KC01, pargyline, The risk or severity of hypertension can be increased when Pargyline is combined with Atropine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Atropine.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Atropine is combined with Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05AG03, penfluridol, Atropine may increase the arrhythmogenic activities of Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Atropine is combined with Pentobarbital.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C08EX02, perhexiline, Atropine may increase the arrhythmogenic activities of Perhexiline.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Atropine is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Atropine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Atropine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Atropine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Atropine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Atropine may decrease the antihypertensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Atropine.]
[V03AB36, phentolamine, Atropine may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Atropine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Atropine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Atropine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Atropine can be decreased when used in combination with Physostigmine.]
[C08CX01, mibefradil, Atropine may increase the arrhythmogenic activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Atropine is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C10AA05, atorvastatin, Atropine may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Atropine is combined with Saquinavir.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA02, eprosartan, Atropine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Atropine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Atropine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C09CA04, irbesartan, Atropine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Atropine which could result in a higher serum level.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Atropine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C03AA05, polythiazide, Atropine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Atropine which could result in a higher serum level.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Atropine is combined with Potassium chloride.]
[C10AA08, pitavastatin, Atropine may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Atropine may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Atropine may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C02CA01, prazosin, Atropine may decrease the antihypertensive activities of Prazosin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Atropine is combined with Antazoline.]
[C01DX02, prenylamine, Atropine may increase the arrhythmogenic activities of Prenylamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Atropine is combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Atropine is combined with Probucol.]
[C01BA02, procainamide, Atropine may increase the arrhythmogenic activities of Procainamide.]
[S01HA05, procaine, The risk or severity of hypertension can be increased when Procaine is combined with Atropine.]
[L01XB01, procarbazine, The risk or severity of hypertension can be increased when Procarbazine is combined with Atropine.]
[C10AB05, fenofibrate, Atropine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Atropine.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BC03, propafenone, Atropine may increase the arrhythmogenic activities of Propafenone.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Atropine is combined with Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Atropine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Atropine.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[B01AC09, epoprostenol, Atropine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Atropine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Atropine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Atropine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Atropine is combined with Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Atropine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[C01BA01, quinidine, Atropine may increase the arrhythmogenic activities of Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Quinine.]
[C02AA01, rescinnamine, Atropine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Atropine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Atropine is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Atropine is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Atropine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Atropine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Atropine is combined with Salicylic acid.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Atropine is combined with Secobarbital.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Atropine.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Selegiline is combined with Atropine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Atropine.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Atropine.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Atropine which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Atropine is combined with Valproic acid.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Atropine which could result in a higher serum level.]
